מדינה: ניו זילנד
שפה: אנגלית
מקור: Medsafe (Medicines Safety Authority)
Potassium bicarbonate 384mg; ; Potassium carbonate 152mg; ; ; Potassium chloride 595mg; ;
Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics
Potassium bicarbonate 384 mg
Effervescent tablet
Active: Potassium bicarbonate 384mg Potassium carbonate 152mg Potassium chloride 595mg Excipient: Acesulfame potassium Aspartame Citric acid Leucine Macrogol 6000 Ribes nigrum Sorbitol
Tube, plastic, PP with PE stopper, 30 tablets
Pharmacy only
Pharmacy only
Kirsch Pharma GmbH
The treatment of potassium deficiency (particularly hypochloremic or hypokalemic alkalosis) associated with diuretic and steroid therapy, vomiting and diarrhoea, ulcerative colitis, steatorrhoea, diabetes insipidus and uncontrolled diabetes mellitus, ileostomy or colostomy patients, cirrhosis and dietary insufficiency.
Package - Contents - Shelf Life: Tube, plastic, PP with PE stopper - 30 tablets - 36 months from date of manufacture stored at or below 25°C - Tube, plastic, PP with PE stopper - 60 tablets - 36 months from date of manufacture stored at or below 25°C
1973-05-17
J:\Regulatory Affairs\Regaff\Chlorvescent\+New Zealand\SACN (Updat data sheet to SPC format) May2019\working files\Chlorvescent Data Sheet May19 - Clean.doc NEW ZEALAND DATA SHEET 1.PRODUCT NAME Chlorvescent Tablets 2.QUALITATIVE AND QUANTITATIVE COMPOSITION Chlorvescent effervescent tablet contains potassium chloride, potassium bicarbonate and citric acid, providing 14mmol potassium (548 mg) and 8 mmol chloride (298 mg) in the form of an acceptable drink. For full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM White or white to yellow, round and flat tablets 4.CLINICAL PARTICULARS 4.1 INDICATIONS Treatment of potassium deficiency (particularly hypochloremic or hypokalemic alkalosis) associated with diuretic and steroid therapy, vomiting and diarrhoea, ulcerative colitis, steatorrhoea, diabetes insipidus and uncontrolled diabetes mellitus, ileostomy or colostomy patients, cirrhosis and dietary insufficiency. 4.2 DOSE AND METHOD OF ADMINISTRATION 1 tablet in half a glass full of water per day is normally sufficient to correct potassium and chloride deficiencies. In more severe depletion, up to 4 tablets (56 mmol potassium and 32 mmol chloride) can be taken daily in divided doses in water. 4.3 CONTRAINDICATIONS Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate any of the following conditions: chronic renal impairment, metabolic acidosis such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns or adrenal insufficiency. Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (eg. spironolactone or triamterene) since the simultaneous administration of these agents can produce severe hyperkalemia. (see also section 4.5, Interaction with other medicines and other forms of interactions) 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Caution is required in cases of קרא את המסמך השלם